Drugs / V-IMMUNE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06954441 | Aug 2025 → Sep 2026 overdue | agammaglobulinemia | On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. | Recruiting | No outcome recorded |
| Phase 3 | NCT06962631 | Jul 2025 → Aug 2026 overdue | autoimmune thrombocytopenia | On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. | Recruiting | No outcome recorded |
| Phase 3 | NCT07017036 | Jul 2025 → Dec 2026 expected | immunodeficiency disease | Virchow Group | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V-IMMUNE | “The Investigational Product (IP) is V-IMMUNE®, normal human immunoglobulin I.P. 5% (5g/100 mL), manufactured from qualified human plasma for intravenous use.” NCT06962631 ↗2“The investigational product is V-IMMUNE®, a 5% human normal immunoglobulin I.P. (5 g/100 mL) manufactured from qualified human plasma for intravenous use.” NCT06954441 ↗ “V-Immune will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks.” NCT07017036 ↗ |
| Known as | normal human immunoglobulin | “The Investigational Product (IP) is V-IMMUNE®, normal human immunoglobulin I.P. 5% (5g/100 mL), manufactured from qualified human plasma for intravenous use.” NCT06962631 ↗ |
| Action | Restore | “IgG replacement therapy” NCT06954441 ↗ |
| Modality | Protein / enzyme biologic | “a 5% human normal immunoglobulin preparation” NCT06954441 ↗ |
| Route | Intravenous | “via intravenous (IV) route” NCT06954441 ↗ |